321-23-3

Basic information

• Product Name: 2-Fluoro-4-bromonitrobenzene
• Synonyms: 2-FLUORO-4-BROMONITROBENZENE;1-BROMO-3-FLUORO-4-NITROBENZENE;4-BROMO-2-FLUORONITROBENZENE;4-BROMO-2-FLUORO-1-NITRO-BENZENE;4-Bromo-2-fluoronitrobenzene 97%;1-Bromo-3-fluoro-4-nitrobenzene 4-Bromo-2-fluoronitrobenzene;4-Bromo-2-fluoronitrobenzene ,97%;4-bromo-2-fluoro-1-nitrobenzene(SALTDATA: FREE)
• CAS NO: 321-23-3
• Molecular Formula: C₆H₃BrFNO₂
• Molecular Weight: 220
• EINECS: 1312995-182-4
• Product Categories: API intermediates;Nitro Compounds;Nitrogen Compounds;Organic Building Blocks;Fluorine series
• Mol File: 321-23-3.mol
• Article Data: 14

Chemical Properties

• Melting Point: 83-86
• Boiling Point: 263.2 °C at 760 mmHg
• Flash Point: 86℃
• Appearance: Pale yellow to orange/Solid
• Density: 1.375
• Vapor Pressure: 0.017mmHg at 25°C
• Refractive Index: 1.579
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: soluble in Methanol
• CAS DataBase Reference: 2-Fluoro-4-bromonitrobenzene(CAS DataBase Reference)
• NIST Chemistry Reference: 2-Fluoro-4-bromonitrobenzene(321-23-3)
• EPA Substance Registry System: 2-Fluoro-4-bromonitrobenzene(321-23-3)

Safety Data

• Hazard Codes: Xn,Xi
• Statements: 20/21/22-36/37/38-22
• Safety Statements: 26-36/37/39-27
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 321-23-3(Hazardous Substances Data)

Usage

Chemical Properties

White to orange to brown solid

Uses

Building block for fused aromatic and heteroaromatic compounds

InChI:InChI=1/C6H3BrFNO2/c7-4-1-2-6(9(10)11)5(8)3-4/h1-3H

Upstream product

• 367-24-8 4-bromo-2-fluoroaniline 
• 586-78-7 para-nitrophenyl bromide 
• 1073-06-9 3-fluorobromobenzene 
• 348-54-9 2-Fluoroaniline 
• 610-38-8 4-bromo-1,2-dinitrobenzene 

Downstream Products

• 189187-32-4 2-Fluoro-4-(diphenylmethyl)nitrobenzene 
• 304875-15-8 5-(3-fluoro-4-nitrophenyl)spiro[cyclohexane-1,3-[3H]indole]-2(1H)-one 
• 305790-83-4 [(5-Bromo-2-nitro-phenyl)-isopropyl-amino]-acetic acid 
• 932700-66-8 N-(5-bromo-2-nitrophenyl)-1-(tetrahydro-2H-pyran-4-yl)-4-piperidinamine 
• 863605-02-1 5-bromo-N-isobutyl-2-nitroaniline 
• 939968-60-2 2-(3-fluoro-4-nitrophenyl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane 
• 813448-98-5 5-bromo-N-ethyl-2-nitro-aniline 
• 1163707-73-0 5-bromo-N-(tert-butyl)-2-nitroaniline 
• 1071527-69-9 N-(2-(5-bromo-2-nitrophenylamino)ethyl)acetamide 
• 1202765-88-5 4-(2-(5-bromo-2-nitrophenyl)-2-(2-(methylthio)pyrimidin-4-yl)acetyl)benzonitrile 
• 1208249-67-5 (5-bromo-2-nitrophenyl)-(6-chloropyridazin-3-ylmethyl)amine 
• 1215106-45-8 ethyl 2-(5-bromo-2-nitrophenyl)-3-(4-fluorophenyl)-3-hydroxyacrylate 
• 302800-13-1 5-bromo-N-methyl-2-nitroaniline 
• 1162696-22-1 N-(5-bromo-2-nitrophenyl)tetrahydro-2H-pyran-4-amine 

Relevant articles and documents

Synthesis and in Vitro Evaluation of 8-Pyridinyl-Substituted Benzo[e]imidazo[2,1-c][1,2,4]triazines as Phosphodiesterase 2A Inhibitors

Phosphodiesterase 2A (PDE2A) is highly expressed in distinct areas of the brain, which are known to be related to neuropsychiatric diseases. The development of suitable PDE2A tracers for Positron Emission Tomography (PET) would permit the in vivo imaging of the PDE2A and evaluation of disease-mediated alterations of its expression. A series of novel fluorinated PDE2A inhibitors on the basis of a Benzoimidazotriazine (BIT) scaffold was prepared leading to a prospective inhibitor for further development of a PDE2A PET imaging agent. BIT derivatives (BIT1–9) were obtained by a seven-step synthesis route, and their inhibitory potency towards PDE2A and selectivity over other PDEs were evaluated. BIT1 demonstrated much higher inhibition than other BIT derivatives (82.9% inhibition of PDE2A at 10 nM). BIT1 displayed an IC50 for PDE2A of 3.33 nM with 16-fold selectivity over PDE10A. This finding revealed that a derivative bearing both a 2-fluoro-pyridin-4-yl and 2-chloro-5-methoxy-phenyl unit at the 8- and 1-position, respectively, appeared to be the most potent inhibitor. In vitro studies of BIT1 using mouse liver microsomes (MLM) disclosed BIT1 as a suitable ligand for 18F-labeling. Nevertheless, future in vivo metabolism studies are required.

Synthesis and in vitro evaluation of diverse heterocyclic diphenolic compounds as inhibitors of DYRK1A

Dual-specificity tyrosine phosphorylation-related kinase 1A (DYRK1A) is a dual-specificity protein kinase that catalyses phosphorylation and autophosphorylation. Higher DYRK1A expression correlates with cancer, in particular glioblastoma present within the brain. We report here the synthesis and biological evaluation of new heterocyclic diphenolic derivatives designed as novel DYRK1A inhibitors. The generation of these heterocycles such as benzimidazole, imidazole, naphthyridine, pyrazole-pyridines, bipyridine, and triazolopyrazines was made based on the structural modification of the lead DANDY and tested for their ability to inhibit DYRK1A. None of these derivatives showed significant DYRK1A inhibition but provide valuable knowledge around the importance of the 7-azaindole moiety. These data will be of use for developing further structure-activity relationship studies to improve the selective inhibition of DYRK1A.

HOMOGENEOUS TIME RESOLVED FLUORESCENCE BASED TEST SYSTEM

The present invention concerns a fluorescence resonance energy transfer based high throughput test system to measure the formation of the HIV gp41 six-helix bundle. In a first embodiment the current invention relates to a homogeneous time resolved fluorescence-based test system comprising a first helical polypeptide consisting essentially of the sequence of IQN36 (SEQ ID NO:1); a second helical polypeptide consisting essentially of the sequence of C34 (SEQ ID NO: 2) wherein said IQN36 is labeled with a light emitting fluorophore and said C34 is labeled with an ultra-violet excitable fluorophore.